Kalaris Therapeutics (KLRS) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 3, 2026, to be held exclusively online for stockholders of record as of April 6, 2026.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper or email copies available upon request by May 22, 2026.

Voting matters and shareholder proposals

• Election of three Class III directors to serve three-year terms expiring at the 2029 annual meeting.

• Advisory vote on executive compensation (say-on-pay) included.

• Advisory vote on the frequency of future executive compensation advisory votes.

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Board recommends voting for all director nominees, for the executive compensation proposal, one year for the frequency of say-on-pay, and for auditor ratification.

Board of directors and corporate governance

• Director nominees are Napoleone Ferrara, M.D., David Hallal, and Leone Patterson.

• Each nominee, if elected, will serve until the 2029 annual meeting and until a successor is duly elected and qualified.